Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
- 31 October 2011
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 123 (1), 19-26
- https://doi.org/10.1016/j.ygyno.2011.06.022
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignanciesGynecologic Oncology, 2011
- Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyJournal of Hematology & Oncology, 2009
- mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the OvaryClinical Cancer Research, 2009
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of RapamycinCancer Research, 2009
- Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic FactorsCancer Epidemiology, Biomarkers & Prevention, 2009
- Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and rapamycinMolecular Cancer Therapeutics, 2009
- Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor‐specific fluorescent ligandsInternational Journal of Cancer, 2008
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsNew England Journal of Medicine, 2008
- In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometryProceedings of the National Academy of Sciences, 2007
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004